Economic Burden Associated with Pulmonary Arterial Hypertension in the United States
This study demonstrates that PAH continues to be associated with a high economic burden and healthcare resource utilization across all payer types within the US healthcare system.
Authors
- Christine Ferro
- A. Watzker (ORCID: https://orcid.org/0009-0003-8897-9339)
- Adnan Alsumali (ORCID: https://orcid.org/0000-0002-5139-3583)
- Karim El‐Kersh (ORCID: https://orcid.org/0000-0003-1285-3628)
- C.H Park (ORCID: https://orcid.org/0000-0003-3135-8235)
- Dominik Lautsch (ORCID: https://orcid.org/0000-0003-3803-1817)
- Gabriela Dieguez
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Arizona (US)
- Milliman (United States) (US)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2024-10-12
- DOI
- https://doi.org/10.1007/s40273-024-01427-2
- Citations
- 13
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.45